Kalaris Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Kalaris Therapeutics Net Debt Growth & History (KLRS)
Kalaris Therapeutics's net debt was −$96.6M for fiscal 2025.
View full Kalaris Therapeutics company overviewKalaris Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$96.6M | −$114.5M | — |
| 2024 | 2024-12-31 | $17.9M | $80.6M | — |
| 2023 | 2023-12-31 | −$62.7M | $8.0M | — |
| 2022 | 2022-12-31 | −$70.7M | $100.9M | — |
| 2021 | 2021-12-31 | −$171.6M | −$57.6M | — |
| 2020 | 2020-12-31 | −$114.0M | −$64.6M | — |
| 2019 | 2019-12-31 | −$49.3M | — | — |
Kalaris Therapeutics quarterly net debt
Q4.19
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$41.8M | $46.7M | — |
| Q1 2026 | 2026-03-31 | −$33.0M | $67.9M | — |
| Q4 2025 | 2025-12-31 | −$96.6M | −$114.5M | — |
| Q3 2025 | 2025-09-30 | −$40.8M | — | — |
| Q2 2025 | 2025-06-30 | −$88.4M | −$91.2M | — |
| Q1 2025 | 2025-03-31 | −$101.0M | −$114.1M | — |
| Q4 2024 | 2024-12-31 | $17.9M | $80.6M | — |
| Q2 2024 | 2024-06-30 | $2.8M | $168.2M | — |
| Q1 2024 | 2024-03-31 | $13.1M | $95.0M | — |
| Q4 2023 | 2023-12-31 | −$62.7M | $8.0M | — |
| Q3 2023 | 2023-09-30 | −$62.7M | $39.4M | — |
| Q2 2023 | 2023-06-30 | −$165.5M | −$116.9M | — |
| Q1 2023 | 2023-03-31 | −$81.9M | −$4.8M | — |
| Q4 2022 | 2022-12-31 | −$70.7M | $100.9M | — |
| Q3 2022 | 2022-09-30 | −$102.2M | $109.7M | — |
| Q2 2022 | 2022-06-30 | −$48.6M | $167.7M | — |
| Q1 2022 | 2022-03-31 | −$77.1M | $81.4M | — |
| Q4 2021 | 2021-12-31 | −$171.6M | −$57.6M | — |
| Q3 2021 | 2021-09-30 | −$211.8M | −$79.1M | — |
| Q2 2021 | 2021-06-30 | −$216.3M | −$148.3M | — |
| Q1 2021 | 2021-03-31 | −$158.4M | — | — |
| Q4 2020 | 2020-12-31 | −$114.0M | −$64.6M | — |
| Q3 2020 | 2020-09-30 | −$132.8M | — | — |
| Q2 2020 | 2020-06-30 | −$68.0M | — | — |
| Q4 2019 | 2019-12-31 | −$49.3M | — | — |
Kalaris Therapeutics net debt trends
Over the last five fiscal years, Kalaris Therapeutics's net debt increased from −$114.0M to −$96.6M, a change of $17.4M. The latest reported quarter, Q2 2026, shows −$41.8M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kalaris Therapeutics source filings ↗